Form 4: Kiniksa Pharmaceuticals Executive Eben Tessari Reports Stock Option Exercise and Share Sale

Eben Tessari, Chief Operating Officer of Kiniksa Pharmaceuticals International, plc, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• Eben Tessari, the Chief Operating Officer of Kiniksa Pharmaceuticals International, plc, filed a Form 4 with the SEC.
• On February 10, 2025, Tessari exercised options to acquire 7,000 Class A Ordinary Shares at a price of $3.80 per share.
• On the same day, Tessari sold 14,000 Class A Ordinary Shares at a weighted average price of $19.57 per share, with individual sales prices ranging from $19.395 to $19.87.
• These transactions were executed under a 10b5-1 trading plan established on April 29, 2024.
• Following these transactions, Tessari directly owns 81,975 Class A Ordinary Shares and 21,049 Share Options.

Sentiment

Score: 5

Explanation: This is a neutral event. An executive exercising options and selling shares is a common occurrence and doesn't necessarily indicate a positive or negative outlook for the company.

Positives

• The transactions were conducted under a pre-arranged 10b5-1 trading plan, which is generally viewed as a transparent and compliant practice.

Industry Context

Form 4 filings are a routine part of the US stock market and are required by the SEC to ensure transparency of trading by corporate insiders. Investors monitor these filings to gain insights into management's perspective on the company's stock.

Comparison to Industry Standards

• It's common for executives at pharmaceutical companies like Kiniksa (comparable to companies like Amgen, Biogen, or Regeneron in terms of development stage) to have stock option plans as part of their compensation.
• The use of a 10b5-1 trading plan is a standard practice to avoid accusations of insider trading, similar to what executives at other publicly traded companies employ.

Stakeholder Impact

• The share sale could have a minor dilutive effect on existing shareholders, but the impact is likely minimal given the relatively small number of shares involved.

Key Dates